111 related articles for article (PubMed ID: 28684410)
21. VEGFR2-Mediated Reprogramming of Mitochondrial Metabolism Regulates the Sensitivity of Acute Myeloid Leukemia to Chemotherapy.
Nóbrega-Pereira S; Caiado F; Carvalho T; Matias I; Graça G; Gonçalves LG; Silva-Santos B; Norell H; Dias S
Cancer Res; 2018 Feb; 78(3):731-741. PubMed ID: 29229602
[TBL] [Abstract][Full Text] [Related]
22. High-dose cytarabine as salvage therapy for relapsed or refractory acute myeloid leukemia--is more better or more of the same?
Wolach O; Itchaki G; Bar-Natan M; Yeshurun M; Ram R; Herscovici C; Shpilberg O; Douer D; Tallman MS; Raanani P
Hematol Oncol; 2016 Mar; 34(1):28-35. PubMed ID: 25689584
[TBL] [Abstract][Full Text] [Related]
23. Nrf2 overexpression increases the resistance of acute myeloid leukemia to cytarabine by inhibiting replication factor C4.
Hu T; Pan C; Zhang T; Ni M; Wang W; Zhang S; Chen Y; Wang J; Fang Q
Cancer Gene Ther; 2022 Nov; 29(11):1773-1790. PubMed ID: 35840666
[TBL] [Abstract][Full Text] [Related]
24. Disulfiram overcomes bortezomib and cytarabine resistance in Down-syndrome-associated acute myeloid leukemia cells.
Bista R; Lee DW; Pepper OB; Azorsa DO; Arceci RJ; Aleem E
J Exp Clin Cancer Res; 2017 Feb; 36(1):22. PubMed ID: 28143565
[TBL] [Abstract][Full Text] [Related]
25. TGF-β1 and CXCL12 modulate proliferation and chemotherapy sensitivity of acute myeloid leukemia cells co-cultured with multipotent mesenchymal stromal cells.
Schelker RC; Iberl S; Müller G; Hart C; Herr W; Grassinger J
Hematology; 2018 Jul; 23(6):337-345. PubMed ID: 29140182
[TBL] [Abstract][Full Text] [Related]
26. SAMHD1 is a biomarker for cytarabine response and a therapeutic target in acute myeloid leukemia.
Schneider C; Oellerich T; Baldauf HM; Schwarz SM; Thomas D; Flick R; Bohnenberger H; Kaderali L; Stegmann L; Cremer A; Martin M; Lohmeyer J; Michaelis M; Hornung V; Schliemann C; Berdel WE; Hartmann W; Wardelmann E; Comoglio F; Hansmann ML; Yakunin AF; Geisslinger G; Ströbel P; Ferreirós N; Serve H; Keppler OT; Cinatl J
Nat Med; 2017 Feb; 23(2):250-255. PubMed ID: 27991919
[TBL] [Abstract][Full Text] [Related]
27. The CCL2/CCR2 Axis Affects Transmigration and Proliferation but Not Resistance to Chemotherapy of Acute Myeloid Leukemia Cells.
Macanas-Pirard P; Quezada T; Navarrete L; Broekhuizen R; Leisewitz A; Nervi B; Ramírez PA
PLoS One; 2017; 12(1):e0168888. PubMed ID: 28045930
[TBL] [Abstract][Full Text] [Related]
28. Smac mimetic primes apoptosis-resistant acute myeloid leukaemia cells for cytarabine-induced cell death by triggering necroptosis.
Chromik J; Safferthal C; Serve H; Fulda S
Cancer Lett; 2014 Mar; 344(1):101-109. PubMed ID: 24184825
[TBL] [Abstract][Full Text] [Related]
29. Evolving Therapies in Acute Myeloid Leukemia: Progress at Last?
DeAngelo DJ; Stein EM; Ravandi F
Am Soc Clin Oncol Educ Book; 2016; 35():e302-12. PubMed ID: 27249736
[TBL] [Abstract][Full Text] [Related]
30. Clinical outcome of treatment with a combined regimen of decitabine and aclacinomycin/cytarabine for patients with refractory acute myeloid leukemia.
Song LX; Xu L; Li X; Chang CK; Zhang Y; Wu LY; He Q; Zhang QX; Li X
Ann Hematol; 2012 Dec; 91(12):1879-86. PubMed ID: 22895556
[TBL] [Abstract][Full Text] [Related]
31. Transient potential receptor melastatin-2 (Trpm2) does not influence murine MLL-AF9-driven AML leukemogenesis or in vitro response to chemotherapy.
Haladyna JN; Pastuer T; Riedel SS; Perraud AL; Bernt KM
Exp Hematol; 2016 Jul; 44(7):596-602.e3. PubMed ID: 27033163
[TBL] [Abstract][Full Text] [Related]
32. Association of a cytarabine chemosensitivity related gene expression signature with survival in cytogenetically normal acute myeloid leukemia.
Yan H; Wen L; Tan D; Xie P; Pang FM; Zhou HH; Zhang W; Liu ZQ; Tang J; Li X; Chen XP
Oncotarget; 2017 Jan; 8(1):1529-1540. PubMed ID: 27903973
[TBL] [Abstract][Full Text] [Related]
33. Tunneling nanotube (TNT) formation is downregulated by cytarabine and NF-κB inhibition in acute myeloid leukemia (AML).
Omsland M; Bruserud Ø; Gjertsen BT; Andresen V
Oncotarget; 2017 Jan; 8(5):7946-7963. PubMed ID: 27974700
[TBL] [Abstract][Full Text] [Related]
34. A phase I trial of ribavirin and low-dose cytarabine for the treatment of relapsed and refractory acute myeloid leukemia with elevated eIF4E.
Assouline S; Culjkovic-Kraljacic B; Bergeron J; Caplan S; Cocolakis E; Lambert C; Lau CJ; Zahreddine HA; Miller WH; Borden KL
Haematologica; 2015 Jan; 100(1):e7-9. PubMed ID: 25425688
[No Abstract] [Full Text] [Related]
35. Facts about FCE (fludarabine, cytarabine, etoposide) in acute myeloid leukemia.
Medeiros BC
Acta Haematol; 2014; 131(4):200-1. PubMed ID: 24296429
[No Abstract] [Full Text] [Related]
36. Hypoxia regulates proliferation of acute myeloid leukemia and sensitivity against chemotherapy.
Drolle H; Wagner M; Vasold J; Kütt A; Deniffel C; Sotlar K; Sironi S; Herold T; Rieger C; Fiegl M
Leuk Res; 2015 Jul; 39(7):779-85. PubMed ID: 25982178
[TBL] [Abstract][Full Text] [Related]
37. Acute myeloid leukemia therapy elicits durable complete response in chemoradio-resistant metastatic paraganglioma.
Sait S; Kobos R; LaQuaglia MP; Pandit-Taskar N; Modak S
Pediatr Blood Cancer; 2017 May; 64(5):. PubMed ID: 27804217
[TBL] [Abstract][Full Text] [Related]
38. Combination therapy of an anticancer drug with the FNIII14 peptide of fibronectin effectively overcomes cell adhesion-mediated drug resistance of acute myelogenous leukemia.
Matsunaga T; Fukai F; Miura S; Nakane Y; Owaki T; Kodama H; Tanaka M; Nagaya T; Takimoto R; Takayama T; Niitsu Y
Leukemia; 2008 Feb; 22(2):353-60. PubMed ID: 17972943
[TBL] [Abstract][Full Text] [Related]
39. Induction of cytosine arabinoside-resistant human myeloid leukemia cell death through autophagy regulation by hydroxychloroquine.
Kim Y; Eom JI; Jeung HK; Jang JE; Kim JS; Cheong JW; Kim YS; Min YH
Biomed Pharmacother; 2015 Jul; 73():87-96. PubMed ID: 26211587
[TBL] [Abstract][Full Text] [Related]
40. Development and molecular characterization of polymeric micro-nanofibrous scaffold of a defined 3-D niche for in vitro chemosensitivity analysis against acute myeloid leukemia cells.
Nair MS; Mony U; Menon D; Koyakutty M; Sidharthan N; Pavithran K; Nair SV; Menon KN
Int J Nanomedicine; 2015; 10():3603-22. PubMed ID: 26028971
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
